UPROSERTIB
GSK2141795
CAS: 1047634-65-0
Molecular Formula: C18H16Cl2F2N4O2
UPROSERTIB - Names and Identifiers
UPROSERTIB - Physico-chemical Properties
| Molecular Formula | C18H16Cl2F2N4O2 |
| Molar Mass | 429.25 |
| Solubility | DMSO: ≥ 36 mg/mL |
| Storage Condition | -20℃ |
| In vitro study | Uprosertib inhibited the phosphorylation levels of multiple AKT substrates in BT474 and LNCaP cells. Uprosertib preferentially inhibits proliferation of tumor cells with activation of the AKT pathway. In the cell lines LNCaP, BT474, A3 and I9.2, Uprosertib also caused cell cycle arrest. In SKOV3 and PEO4 cells, Uprosertib leads to growth arrest and enhances cisplatin-induced apoptosis. |
| In vivo study | In mice with BT474 breast cancer tumors, Uprosertib (100 mg/kg, p.o.) resulted in 61% tumor growth inhibition. Uprosertib (30 mg/kg, p.o.) also induced 61% tumor growth inhibition in SKOV3 ovarian cancer tumor-growing mice. |
UPROSERTIB - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.33 ml | 11.648 ml | 23.297 ml |
| 5 mM | 0.466 ml | 2.33 ml | 4.659 ml |
| 10 mM | 0.233 ml | 1.165 ml | 2.33 ml |
| 5 mM | 0.047 ml | 0.233 ml | 0.466 ml |
Last Update：2024-01-02 23:10:35
UPROSERTIB - Introduction
GSK2141795 is a compound with the chemical name (3S,4R)-3-[(4-tert-Butoxyphenyl)methyl]-4-[(2-fluorophenyl)methyl]pyrrolidine. It is a selective mutant B- RAF inhibitor that can inhibit the activity of mutant B- RAF proteins in cells. This compound is mainly used for tumor treatment, especially for tumors caused by mutant B- RAF such as malignant melanoma. The preparation method of GSK2141795 is synthesized by organic synthesis method.
regarding the safety information of GSK2141795, the following points should be noted:
1. GSK2141795 is a chemical drug and should be used in accordance with relevant safety practices, such as wearing appropriate personal protective equipment and avoiding contact with skin, eyes and respiratory tract.
2. In storage and handling to avoid unforeseen reactions with other drugs, chemical substances, so as to avoid the production of dangerous substances.
3. GSK2141795 may have potential hazards to human health, such as irritation, toxicity, etc. Therefore, the necessary safety assessment and laboratory experiments should be carried out before use.
4. When using GSK2141795, you should follow the recommendations of scientists or doctors, and use it strictly in accordance with the given dosage and usage. For pregnant women, lactating women, children and the elderly, due to the lack of sufficient research data, should be avoided or used with caution.
regarding the safety information of GSK2141795, the following points should be noted:
1. GSK2141795 is a chemical drug and should be used in accordance with relevant safety practices, such as wearing appropriate personal protective equipment and avoiding contact with skin, eyes and respiratory tract.
2. In storage and handling to avoid unforeseen reactions with other drugs, chemical substances, so as to avoid the production of dangerous substances.
3. GSK2141795 may have potential hazards to human health, such as irritation, toxicity, etc. Therefore, the necessary safety assessment and laboratory experiments should be carried out before use.
4. When using GSK2141795, you should follow the recommendations of scientists or doctors, and use it strictly in accordance with the given dosage and usage. For pregnant women, lactating women, children and the elderly, due to the lack of sufficient research data, should be avoided or used with caution.
Last Update：2024-04-09 21:04:16
Supplier List
Spot supply
Product Name: GSK2141795 Visit Supplier Webpage Request for quotationCAS: 1047634-65-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: GSK2141795 Visit Supplier Webpage Request for quotationCAS: 1047634-65-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History